BioCentury
ARTICLE | Product Development

With an eye toward M&A, Vivace aims to establish POC for emerging solid tumor target TEAD

Compound could deliver first clinical signal for therapies against Hippo pathway

May 4, 2021 7:40 PM UTC

Vivace believes it has charted a capital-efficient path to the first clinical proof of concept for therapies against the cancer- and fibrosis-driving Hippo pathway, with enough runway to reach an exit.

Vivace Therapeutics Inc., which has raised $70 million in venture funds since its founding in 2014, announced Tuesday it finished dosing the first cohort of solid tumor patients in a Phase I study of pan-TEAD inhibitor VT3989. The company described the program’s discovery, optimization and preclinical activity in a Molecular Cancer Therapeutics paper published last month. ...